Table 2.
Characteristics of COVID-19 patients with and without liver injury
| No liver injury (n=179) | Liver injury (n=177) | P-value | |
|---|---|---|---|
| Clinical and epidemiological characteristics | |||
| Female, n (%) | 104 (58.10) | 59 (33.33) | <0.001 |
| Male, n (%) | 75 (41.90) | 118 (66.67) | |
| Age (years) | 53.5 (43.5–66.5) | 59 (45–68.5) | 0.072 |
| Length of stay (days) | 20.5 (17–29) | 30 (21–37) | <0.001 |
| Clinical type on admission, n (%) | |||
| Mild | 5 (2.79) | 1 (0.56) | <0.001 |
| Ordinary | 157 (87.71) | 128 (72.32) | |
| Severe | 10 (5.59) | 22 (12.43) | |
| Critical | 7 (3.91) | 26 (14.69) | |
| Symptoms, n (%) | |||
| Fever | 137 (76.54) | 141 (79.66) | 0.476 |
| Dry cough | 130 (72.63) | 132 (74.58) | 0.676 |
| Expectoration | 79 (44.13) | 82 (46.33) | 0.678 |
| Fatigue | 62 (34.64) | 63 (35.59) | 0.85 |
| Dyspnea | 11 (6.15) | 32 (18.08) | 0.001 |
| Headache | 4 (2.23) | 11 (6.21) | 0.062 |
| Diarrhea | 4 (2.23) | 9 (5.08) | 0.152 |
| Hemorrhage | 5 (2.79) | 2 (1.13) | 0.258 |
| Comorbidities, n (%) | |||
| Hypertension | 30 (16.76) | 51 (28.81) | 0.007 |
| Diabetes | 12 (6.70) | 26 (14.69) | 0.015 |
| Cardiovascular disease | 4 (2.23) | 15 (8.47) | 0.009 |
| Cerebrovascular disease | 4 (2.29) | 9 (5.14) | 0.265 |
| COPD | 3 (1.68) | 6 (3.39) | 0.303 |
| Malignancy | 0 | 4 (2.26) | 0.043 |
Abbreviation: COPD, chronic obstructive pulmonary disease.